Minireview: Preclinical Studies of Water-insoluble Camptothecin Congeners: Cytotoxicity, Development of Resistance, and Combination Treatments

Clinical Cancer Research

Volumn 1, Issue 11, 1995, Pages 1235-1244

  Pantazis, Panayotis ^a  

^a St Joseph's Medical Center Houston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; CISPLATIN; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; TUMOR NECROSIS FACTOR; VINCRISTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER CHEMOTHERAPY; CELL CYCLE; DRUG RESISTANCE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COMBINED MODALITY THERAPY; DNA DAMAGE; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FORECASTING; HUMAN; HYPERTHERMIA, INDUCED; MICE; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED;

EID: 0028824483     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (140)

1. Lopez-Meyer, M., Nessler, C. L., and McKnight, T. D. Sites of accumulation of the antitumor alkaloid camptothecin in Camptotheca acuminata. Planta Med., 60: 558–560, 1994.
2. Wall, M. E., Wani, M. C., Cook, C. E., Palmer, K. H., McPhail, A. T., and Sim, G. A. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc., 88: 3888–3890, 1966.
3. Horwitz, M. S., and Horwitz, S. B. Intracellular degradation of HeLa and adenovirus type 2 DNA induced by camptothecin. Biochem. Biophys. Res. Commun., 45: 723–727, 1971.
4. Kessel, D. Effects of camptothecin on RNA synthesis in leukemia L1210 cells. Biochim. Biophys. Acta, 246: 225–232, 1971.
5. Horwitz, S. B., Chang, C-K., and Grollman, A. P. Studies on camptothecin. 1. Effects on nucleic acid and protein synthesis. Mol. Pharmacol., 7; 632–644, 1971.
6. Wu, R. S., Kumar, A., and Warner, J. R. Ribosomal formation is blocked by camptothecin, a reversible inhibitor of RNA synthesis. Proc. Natl. Acad. Sci. USA, 68: 3009–3014, 1971.
7. Kessel, D., Bosmann, H. B., and Lohr, K. Camptothecin effects on DNA synthesis of murine leukemia cells. Biochim. Biophys. Acta, 269: 210–216, 1972.
8. Abelson, H. T., and Penman, S. Selective interruption of high molecular weight RNA synthesis in HeLa cells by camptothecin. Nature (Lond.), 237: 144–146, 1972.
9. Bendixen, C, Thomsen, B., Alsner, J., and Westergaard, O. Camptothecin-stabilized topoisomerase I-DNA adducts cause premature termination of transcription. Biochemistry, 12: 5613–5619, 1990.
10. Gottlieb, J. A., Guarino, A. M., Call, J. B., and Block, J. B. Preliminary pharmacological and clinical evaluation of camptothecin sodium (NCS 100880). Cancer Chemother. Rep., 54: 461–470, 1970.
11. Moertel, C. G., Schutt, A. J., Reitemeier, R. J., and Hahn, R. G. Phase II study of camptothecin (NSC 100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep., 56: 95–101, 1972.
12. Gottlieb, J. A., and Luce, J. K. Treatment of malignant melanoma with camptothecin (NSC 100880). Cancer Chemother. Rep., 56: 103–105, 1972.
13. Muggia, F. M., Creaven, P. T., Hansen, H. H., Cohen, M. N., and Selawny, D. S. Phase I clinical trials of weekly and daily treatment with camptothecin (NSC 100880). Correlation with clinical studies. Cancer Chemother. Rep., 56: 515–521, 1972.
14. Wall, M. E., and Wani, M. C. Chemistry and antitumor activities of camptothecins. In: M. Potmesil and K. W. Kohn (eds.), DNA Topoisomerases in Cancer, pp. 93–102. New York: Oxford University Press, 1991.
15. Hsiang, Y-H., Hertzberg, R., Hecht, S., and Liu, L. F. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260: 14873–14878, 1985.
16. Hsiang, Y-H., and Liu, L. F. Identification of mammalian topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res., 48: 1722–1726, 1988.
17. Hertzberg, R., Caranfa, M., and Hecht, S. On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex. Biochemistry, 28: 4629–4638, 1989.
18. Jaxel, C., Kohn, K. W., Wani, M. C., Wall, M. E., and Pommier, Y. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity. Cancer Res., 49: 1465–1469, 1989.
19. Hsiang, Y-H., Liu, L. F., Wall, M. E., Wani, M. C., Kirshenbaum, S., Silber, R., and Potmesil, M. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res., 49: 4385–4389, 1989.
20. Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., and Potmesil, M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science (Washington DC), 246: 1046–1048, 1989.
21. Giovanella, B. C., Hinz, H. R., Kozielski, A. J., Stehlin, J. S., Silber, R., and Potmesil, M. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20(5)-camptothecin. Cancer Res., 51: 3052–3055, 1991.
22. Pantazis, P., Hinz, H. R., Mendoza, J. T., Kozielski, A. J., Williams, L. J., Stehlin, J. S., and Giovanella, B. C. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice by camptothecins. Cancer Res., 52: 3980–3987, 1992.
23. Wall, M. E., and Wani, M. C. Antineoplastic agents from plants. Annu. Rev. Pharmacol. Toxicol., 17: 117–132, 1977.
24. Kunimoto, T., Nitta, K., Tanaka, T., Uehara, N., Baba, H., Takeuchi, M., Yokokura, T., Sawada, S., Miyasaka, T., and Mutai, M. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res., 47: 5944–5947, 1987.
25. Kingsbury, W. D., Boehm, J. C., Jakas, D. R., Holden, K. G., Hecht, S. M., Gallagher, G., Caranfa, M. J., McCabe, F. L., Faucette, L. F., Johnson, R. K., and Hertzberg, R. P. Synthesis of water-soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J. Med. Chem., 34: 98–107, 1991.
26. Burke, T. G., and Mi, Z. Preferential binding of the carboxylate form of camptothecin by human serum albumin. Anal. Biochem., 212: 285–287, 1993.
27. Mi, Z., and Burke, T. G. Differential interactions of camptothecin lactone and carboxylate forms with human blood components. Biochemistry, 33: 10325–10336, 1994.
28. Burke, T. G., Munshi, C. B., Mi, Z., and Jiang, Y. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs. J. Pharm. Sci., 84: 518–519, 1995.
29. Eckardt, J. R., Burris, H. A., Rothenberg, M. L., Von Hoff, D. D., and Kuhn, J. G. Topoisomerase I inhibitors: promising novel compounds. Contemp. Oncol. Jan.: 47–60, 1993.
30. Creemers, G. J., Lund, B., and Verweij, J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat. Rev., 20: 73–96, 1994.
31. Bowen, K., Fields, S., and Buris, H. Topoisomerase I inhibitors: a new class of anticancer agents. Adv. Oncol., 10: 16–21, 1994.
32. Potmesil, M. Camptothecins: from bench research to hospital wards. Cancer Res., 54: 1431–1439, 1994.
33. Tanizawa, A., Fujimori, A., Fujimori, Y., and Pommier, Y. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J. Natl. Cancer Inst., 86: 836–842, 1994.
34. Pantazis, P., Mendoza, J. T., Kozielski, A. J., Natelson, E. A., and Giovanella, B. C. 9-Nitro-camptothecin delays growth of U-937 leukemia tumors in nude mice and is cytotoxic or cytostatic for human myelomonocytic leukemia lines in vitro. Eur. J. Haematol., 50: 81–89, 1993.
35. Pantazis, P., Early, J. A., Kozielski, A. J., Mendoza, J. T., Hinz, H. R., and Giovanella, B. C. Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitro-camptothecin: differential response of nontumorigenic and tumorigenic human breast cells in vitro. Cancer Res., 53: 1577–1582, 1993.
36. Pantazis, P., Kozielski, A. J., Mendoza, J. T., Early, J. A., Hinz, H. R., and Giovanella, B. C. Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro. Int. J. Cancer, 53: 863–871, 1993.
37. Pantazis, P., Early, J. A., Mendoza, J. T., DeJesus, A. R., and Giovanella, B. C. Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro. Cancer Res., 54: 771–776, 1994.
38. Pantazis, P., Kozielski, A. J., Vardeman, D. M., Petry, E. R., and Giovanella, B. C. Efficacy of camptothecin congeners in the treatment of human breast carcinoma xenografts. Oncol. Res., 5: 273–281, 1993.
39. Pantazis, P., Kozielski, A., Rodriguez, R., Petry, E., Wall, M., and Giovanella, B. C. Therapeutic efficacy of camptothecin-derivatives against human malignant melanoma xenografts. Melanoma Res., 4: 5–10, 1994.
40. Stehlin, J. S., Natelson, E. A., Hinz, H. R., Giovanella, B. C., de Ipolyi, P. D., Fehir, K. M., Trezona, T. P., Vardeman, D. M., Harris, N. J., Marcee, A. K., Kozielski, A. J., and Ruiz-Razura, A. Phase I clinical trial and pharmacokinetics results with oral administration of 20(5)-camptothecin. In: M. Potmesil and H. Pinedo (eds.), Camptothecins: New Anticancer Agents, pp. 59–65. Boca Raton, FL: CRC Press, Inc., 1995.
41. Muggia, F. M., and Burris, H. A. Clinical development of topoisomerase-interactive drugs. Adv. Pharmacol., 29A: 1–31, 1995.
42. In: M. Potmesil and H. Pinedo (eds.), Camptothecins: New Anticancer Drugs. Boca Raton, FL: CRC Press, Inc., 1995.
43. Rubin, E., Wood, V., Bharti, A., Trites, D., Lynch, C, Hurwitz, S., Bartel, S., Levy, S., Rosowsky, A., Toppmeyer, D., and Kufe, D. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin. Cancer Res., 1: 269–276, 1995.
44. Giovanella, B. Topoisomerase I inhibitors. In: B. Teicher (ed.), Cancer Drug Discovery. New York: Academic Press, in press, 1995.
45. Hinz, H. R., Harris, N. J., Natelson, E. A., and Giovanella, B. C. Pharmacokinetics of the in vivo and in vitro conversion of 9-nitro-20(S)-camptothecin to 9-amino-20(S)-camptothecin in human, dog and mouse. Cancer Res., 54: 3096–3100, 1994.
46. Pantazis, P., Harris, N., Mendoza, J., and Giovanella, B. Conversion of 9-nitro-camptothecin to 9-amino-camptothecin by human blood cells in vitro. Eur. J. Haematol., 53: 246–248, 1994.
47. Pantazis, P., Harris, N., Mendoza, J., and Giovanella, B. The role of pH and serum albumin in the metabolic conversion of 9-nitrocamptothecin to 9-aminocamptothecin by human hematopoietic and other cells. Eur. J. Haematol., 55: 211–213, 1995.
48. Caron, P., and Wang, J. C. DNA topoisomerases as targets of therapeutics: a structural overview. In: T. Ando, H. Ikeda, and M. Oguro (eds.), Molecular Biology of DNA Topoisomerases and Its Application to Chemotherapy, pp. 1–18. Boca Raton, FL: CRC Press, Inc., 1993.
49. In: T. Andoh, H. Ikeda, and M. Oguro (eds.), Molecular Biology of DNA Topoisomerases and Its Application to Chemotherapy. Boca Raton, FL: CRC Press, Inc., 1993.
50. Liu, L. F. DNA topoisomerases: biochemistry and molecular biology. Adv. Pharmacol., 29A: 1994.
51. Pommier, Y., Jaxel, C, Heise, C. R., Kerrigan, D., and Kohn, K. W. Structure-activity relationship of topoisomerase I inhibition by camptothecin derivatives: evidence for the existence of a ternary complex. In: M. Potmesil and K. W. Kohn (eds.), DNA Topoisomerase in Cancer, pp. 121–132. New York: Oxford University Press, 1991.
52. Jaxel, C, Capranico, G., Kerrigan, D., Kohn, K., and Pommier, Y. Effect of local DNA sequence on topoisomerase I cleavage in the presence or absence of camptothecin. J. Biol. Chem., 266: 20418–20423, 1991.
53. Porter, S. E., and Champoux, J. J. The basis for camptothecin enhancement of DNA breakage by eukaryotic topoisomerase I. Nucleic Acids Res., 17: 8521–8532, 1989.
54. Champoux, J. J. DNA is linked to the rat liver nicking-dosing enzyme by a phosphodiester bond to tyrosine. J. Biol. Chem., 256: 4805–4809, 1981.
55. Leteurtre, F., Fesen, M., Kohlhagen, G., Kohn, K. W., and Pommier, Y. Specific interaction of camptothecin, a topoisomerase I inhibitor, with guanine residues of DNA detected by photoactivation at 365 nm. Biochemistry, 32: 8955–8962, 1993.
56. Zhang, H., D'Arpa, P., and Liu, L. A model for tumor cell killing by topoisomerase poisons. Cancer Cells (Cold Spring Harbor), 2: 23–27, 1990.
57. Hsiang, Y-H., Lihou, M. G., and Liu, L. F. Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res., 49: 5077–5082, 1989.
58. Tsao, Y-P., Russo, A., Nyamuswa, G., Silber, R., and Liu, L. F. Interaction between replication forks and topoisomerase I-DNA cleavable complexes: studies in a cell-free SV40 DNA replication system. Cancer Res., 53: 5908–5914, 1993.
59. Yoshida, A., Ueda, T., Wano, Y., and Nakamura, T. DNA damage and cell killing by camptothecin and its derivative in human leukemia HL-60 cells. Jpn. J. Cancer Res., 84: 566–573, 1993.
60. Gallo, R. C., Whang-Peng, J., and Adamson, R. H. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin. J. Natl. Cancer Inst., 46: 789–795, 1971.
61. Del Bino, G., Skierski, J. S., and Darzynkiewicz, Z. Diverse effects of camptothecin, an inhibitor of topoisomerase I, on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KG-1) leukemia cells. Cancer Res., 50: 5746–5750, 1990.
62. D'Arpa, P., Beardmore, C, and Liu, L. F. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res., 50: 6919–6924, 1990.
63. Del Bino, G., and Darzynkiewicz, Z. Camptothecin, teniposide, or 4′-(9-acridinyl-amino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S-phase of HL-60 cells. Cancer Res., 51: 1165–1169, 1991.
64. Kharbanda, S., Rubin, E., Gunji, H., Hinz, H., Giovanella, B., Pantazis, P., and Kufe, D. Camptothecin and its derivatives induce expression of the c-jun protooncogene in human myeloid leukemia cells. Cancer Res., 51: 6636–6642, 1991.
65. Darzynkiewicz, Z., Bruno, S., Del Bino, G., Gorczyca, W., Hotz, M. A., Lassota, P., and Traganos, F. Features of apoptotic cells by flow cytometry. Cytometry, 13: 795–808, 1992.
66. Lanza, A., Tornaletti, S., Stefanini, M., Evans, H. H., Ricanati, M., Astaldi-Ricotti, J., and Pedrini, A. M. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases. Carcinogenesis (Lond.), 14: 1759–1763, 1993.
67. Ryan, A. J., Squires, S., Strutt, H. L., Evans, A., and Johnson, R. T. Different fates of camptothecin-induced replication fork-associated double-strand DNA breaks in mammalian cells. Carcinogenesis (Lond.), 15: 823–828, 1994.
68. Kohn, K. W., Jackman, J., and O'Connor, P. M. Cell cycle control and cancer chemotherapy. J. Cell. Biochem., 54: 440–452, 1994.
69. Smith, P. J., Makinson, T. A., and Watson, J. V. Enhanced sensitivity to camptothecin in ataxia telangiectasia cells and its relationship with the expression of DNA topoisomerase I. Int. J. Radiat. Biol., 55: 217–231, 1989.
70. Squires, S., Ryan, A. J., Strutt, H. L., and Johnson, R. T. Hypersensitivity of Cockayne's syndrome cells to camptothecin is associated with the generation of abnormally high levels of double strand breaks in nascent DNA. Cancer Res., 53: 2012–2019, 1993.
71. Chatterjee, S., Cheng, M. F., and Berger, N. A. Hypersensitivity to clinically useful alkylating agents and radiation in poly(ADP-ribose) polymerase-deficient cell lines. Cancer Commun., 2: 401–407, 1990.
72. Tsao, Y-P., D'Arpa, P., and Liu, L. F. The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Res., 52: 1823–1829, 1992.
73. Shimizu, T., O'Connor, P. M., Kohn, K. W., and Pommier, Y. Unscheduled activation of cyclin Bl/cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage. Cancer Res., 55: 228–231, 1995.
74. Gong, J., Ardelt, B., Traganos, F., and Darzynkiewicz, Z. Unscheduled expression of cyclin B1 and cyclin E in several leukemic and solid tumor cell lines. Cancer Res., 54: 4285–4288, 1994.
75. Houghton, J. A., Harwood, F. G., and Houghton, P. J. Cell cycle control processes determine cytostasis or cytotoxicity in thymineless death of colon cancer cells. Cancer Res., 54: 4967–4973, 1994.
76. Goldie, J. H. Drug resistance. In: M. C. Perry (ed.), The Chemotherapy Source Book, pp. 54–66. Baltimore, MD: Williams & Wilkins, 1992.
77. Pratt, W. B., Ruddon, R. W., Ensminger, W. D., and Maybaum, J. Resistance to anticancer drugs. In: The Anticancer Drugs, Ed. 2, pp. 50–66. New York: Oxford University Press, 1994.
78. Eng, W. K., Faucette, L., Johnson, R. K., and Sternglanz, R. Evidence that DNA topoisomerase I is necessary for the cytotoxic effects of camptothecin. Mol. Pharmacol., 34: 755–760, 1989.
79. Chang, J-Y., Dethlefsen, L. A., Barley, L. R., Zhou, B. S., and Cheng, Y-C. Characterization of camptothecin-resistant Chinese hamster lung cells. Biochem. Pharmacol., 43: 2443–2452, 1992.
80. Sugimoto, Y., Tsukahara, S., Oh-Hara, T., Isoe, T., and Tsunio, T. Decreased expression of topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody. Cancer Res., 50: 6925–6930, 1990.
81. Eng, W. K., McCabe, F. L., Tan, K. B., Mattern, M. R., Hofmann, G. A., Woessner, R. D., Hertzberg, R. P., and Johnson, R. K. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol. Pharmacol., 38: 471–480, 1990.
82. Kjeldsen, E., Bonven, B., Andoh, T., Ishii, K., Okada, K., Bolund, L., and Westergaard, O. Characterization of a camptothecin-resistant human DNA topoisomerase. J. Biol. Chem., 263: 3912–3916, 1988.
83. Tanizawa, A., and Pommier, Y. Topoisomerase I alteration in a camptothecin-resistant cell line derived from Chinese hamster DC3F cells in culture. Cancer Res., 52: 1848–1854, 1992.
84. Madelaine, I., Prost, S., Naudin, A., Riou, G., Lavelle, F., and Riou, J-F. Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation. Biochem. Pharmacol., 45: 339–348, 1993.
85. Gromova, I. I., Kjeldsen, E., Svejstrup, J. Q., Alsner, J., Christiansen, K., and Westergaard, O. Characterization of an altered DNA catalysis of camptothecin-resistant eukaryotic topoisomerase I. Nucleic Acids Res., 21: 593–600, 1993.
86. Rubin, E., Pantazis, P., Bharti, T., Toppmeyer, D., Giovanella, B. C., and Kufe, D. Identification of a mutant human topoisomerase I with intact catalytic activity and resistance to 9-nitrocamptothecin. J. Biol. Chem., 269: 2433–2439, 1994
87. Pantazis, P., Mendoza, J. T., DeJesus, A., Rubin, E., Kufe, D., and Giovanella, B. C. Partial characterization of human leukemia U-937 cell sublines resistant to 9-nitro-camptothecin. Eur. J. Haematol., 53: 135–144, 1994.
88. Gerlach, J. H., Kartner, N., Bell, D. R., and Ling, V. Multidrug resistance. Cancer Surv., 5: 25–46, 1986.
89. Endicott, J. A., and Ling, V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem., 58: 137–171, 1989.
90. Nooter, K., and Sonneveld, P. Clinical relevance of P-glycoprotein expression in haematological malignancies. Leuk. Res., 18: 233–243, 1994.
91. Friedland, M. L. Combination chemotherapy. In: M. C. Perry (ed.), The Chemotherapy Source Book, pp. 90–95. Baltimore, MD: Williams & Wilkins, 1992.
92. Pratt, W. B., Ruddon, R. W., Ensminger, W. D., and Maybaum, J. Choice of drugs for cancer chemotherapy. In: The Anticancer Drugs, Ed. 2, pp. 235–246. New York: Oxford University Press, 1994.
93. Kaufmann, S. H. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res., 57: 1129–1136, 1991.
94. Bertrand, R., O'Conner, P. M., Kerrigan, D., and Pommier, Y. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. Eur. J. Cancer, 28A: 743–748, 1992.
95. Taudou, G., Portemer, C, Jaxel, C, and Duguet, M. Inhibition of DNA synthesis and DNA fragmentation in stimulated splenocytes by the concerted action of topoisomerase I and II poisons. Biochem. Pharmacol., 45: 331–337, 1993.
96. Pantazis, P., Mendoza, J., DeJesus, A., Early, J., Shaw, M., and Giovanella, B. Development of resistance to 9-nitro-camptothecin by human leukemia U-937 cells in vitro correlates with altered sensitivities to several anticancer drugs. Anticancer Drugs, 5: 473–479, 1994.
97. Pantazis, P., Vardeman, D., Mendoza, J., Early, J., Kozielski, A., DeJesus, A., and Giovanella, B. Sensitivity of camptothecin-resistant human leukemia cells and tumors to anticancer drugs with diverse mechanisms of action. Leuk. Res., 19: 45–55, 1995.
98. Beck, W. T. Unknotting the complexities of multidrug resistance: the involvement of DNA topoisomerases in drug action and resistance. J. Natl. Cancer Inst., 81: 1683–1685, 1989.
99. Tan, K. B., Mattern, M. R., Eng, W-K., McCabe, F. L., and Johnson, R. K. Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors. J. Natl. Cancer. Inst., 81: 1732–1735, 1989.
100. Sugimoto, Y., Tsukahara, S., Oh-Hara, T., Liu, L. F., and Tsuruo, T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res., 50: 7962–7965, 1990.
101. Bradley, G., Naik, M., and Ling, V. P-glycoprotein expression in multidrug-resistant human ovarian carcinoma cell lines. Cancer Res., 49: 2790–2796, 1989.
102. Kirschner, L. S., Greenberger, L. M., Hsu, S. I-H., Yang, C-P. H., Cohen, D., Piekarz, R. L., Castillo, G., Han, E. K-H., Yu, L., and Horwitz, S. B. Biochemical and genetic characterization of the multidrug resistance phenotype in murine macrophage-like J774.2 cells. Biochem. Pharmacol., 43: 77–87, 1992.
103. Fairchild, C. R., Ivy, S. P., Kao-Shan, C-S., Whang-Peng, J., Rosen, N., Israel, M. A., Melera, P. W., Cowan, K. H., and Goldsmith, M. E. Isolation of amplified and overexpressed DNA sequences from Adriamycin-resistant human breast cancer cells. Cancer Res., 47: 5141–5148, 1987.
104. Ganapathi, R., Grabowski, D., Ford, J., Heiss, C, Kerrigan, D., and Pommier, Y. Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomersase II-mediated DNA cleavage. Cancer Commun., 1: 217–224, 1989.
105. Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Dunkan, A. M. V., and Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (Washington DC), 258: 1650–1654, 1992.
106. Schneider, E., Horton, J. K., Yang, C-H., Nakagawa, M., and Cowan, K. H. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res., 54: 152–158, 1994.
107. Grant, C. E., Valdimarsson, G., Hipfner, D. R., Amquist, K. C., Cole, S. P. C., and Deeley, R. G. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res., 54: 357–361, 1994.
108. Kruh, G. D., Chan, A., Myers, K., Gaughan, K., Miki, T., and Aaronson, S. A. Expression of complementary DNA library transfer establishes mrp as a multidrug resistance gene. Cancer Res., 54: 1649–1652, 1994.
109. Slapak, C. A., Mizunuma, N., and Kufe, D. W. Expression of the multidrug resistance associated protein and P-glycoprotein in doxorubicin-selected human myeloid leukemia cells. Blood, 84: 3113–3121, 1994.
110. Slapak, C. A., Fracasso, P. M., Martell, R. L., Toppmeyer, D. L., Lecerf, J-M., and Levy, S. B. Overexpression of the multidrug resistance-associated protein gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells. Cancer Res., 54: 5607–5613, 1994
111. Zaman, G. J. R., Versantvoort, C. H. M., Smit, J. J. M., Eijdems, E. W. H. M., de Haas, M., Smith, A. J., Broxterman, H. J., Mulder, N. H., de Vries, E. G. E., Baas, F., and Borst, P. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res., 53: 1747–1750, 1993.
112. Chen, A. Y., Potmesil, M., Wall, M. E., Wani, M. C., and Liu, L. F. Camptothecin overcomes MDRI -mediated resistance in human KB carcinoma cells. Cancer Res., 51: 6039–6044, 1991.
113. Raefsky, E. L., and Wasserman, T. H. Combined modality therapy. In: M. C. Perry, (ed.), The Chemotherapy Source Book, pp. 110–129. Baltimore, MD: Williams & Wilkins, 1992.
114. In: E. W. Gerner and T. C. Cetas (eds.), Hyperthermic Oncology 1992, Proceedings of the 6th International Congress on Hyperthermic Oncology, Vol. 2. Tucson, AZ: 1993.
115. Hahn, G. M. Thermal enhancement of the actions of anticancer agents. In: G. M. Hahn (ed.), Hyperthermia and Cancer, pp. 55–86. New York: Plenum Publishing Corp., 1982.
116. Musk, S. R. R., and Steel, G. G. The inhibition of cellular recovery in human tumor cells by inhibitors of topoisomerase I. Br. J. Cancer, 62: 364–367, 1990.
117. Boothman, D. A., Wang, M., Schea, R. A., Burrows, H. L., Strickfaden, S., and Owens, J. K. Posttreatment exposure to camptothecin unbalances the lethal effects of X-rays on radioresistant malignant melanoma cells. Int. J. Radiat. Oncol. Biol. Phys., 24: 939–948, 1992.
118. Boscia, R. E., Korbut, T., Holden, S. A., Ara, G., and Teicher, B. A. Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum (II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo. Int. J. Cancer, 53: 118–123, 1993.
119. Falk, S. J., and Smith, P. J. DNA damaging and cell cycle effects of the topoisomerase I poison camptothecin in irradiated human cells. Int. J. Radiat. Biol., 61: 749–757, 1992.
120. Del Bino, G., Bruno, S., Yi, P. N., and Darzynkiewicz, Z. Apoptotic cell death triggered by camptothecin or teniposide. The cell cycle specificity and effects of ionizing radiation. Cell. Prolif., 25: 537–548, 1992.
121. Gorczyca, W., Gong, J., Ardelt, B., Traganos, F., and Darzynkiewicz, Z. The cell cycle related differences in susceptibility of HL-60 cells. Cancer Res., 53: 3186–3192, 1993.
122. Hennequin, C, Giocanti, N., Balosso, J., and Favaudon, Y. Interaction of ionizing radiation with the topoisomerase I poison camptothecin in growing V-79 and HeLa cells. Cancer Res., 54: 1720–1728, 1994.
123. Boothman, D. A., Fukunaga, N., and Wang, M. Down-regulation of topoisomerase I in mammalian cells following ionizing radiation. Cancer Res., 54: 4618–4626, 1994.
124. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304–6311, 1991.
125. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. W., and Kastan, M. D. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491–7495, 1992.
126. O'Connor, P. M., and Kohn, K. W. A fundamental role for cell cycle regulation in the chemosensitivity of cancer cells? Semin. Cancer Biol., 3: 409–416, 1992.
127. O'Connor, P. M., Jackman, J., Jondle, D., Bhatia, K., Magrath, I., and Kohn, K. W. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res., 53: 4776–4780, 1993.
128. Lee, J. M., and Bernstein, A. p53 mutations increase resistance to ionizing radiation. Proc. Natl. Acad. Sci. USA, 90: 5742–5746, 1993.
129. McIlwrath, A. J., Vasey, P. A., Ross, G. M., and Brown, R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res., 54: 3718–3722, 1994.
130. Lambert, R. A. Demonstration of the greater susceptibility to heat of sarcoma cells. J. Am. Med. Assoc., 59: 2147–2148, 1912.
131. Giovanella, B. C., Stehlin, J. S., and Yim, S. O. Correlation of the thermosensitivity of cells to their malignant potential. Ann. NY Acad. Sci., 335: 206–214, 1980.
132. Fisher, G. A., and Hahn, G. M. Enhancement of cis-platinum(II) diamminedichloride cytotoxicity by hyperthermia. Natl. Cancer Inst. Mongr., 61: 255–257, 1982.
133. Watanabe, N., Niitsu, Y., Umeno, H., Sone, H., Neda, H., Yamauchi, N., Maeda, M, and Urushizaki, I. Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Res., 48: 650–653, 1988.
134. Niitsu, Y., Watanabe, N., Umeno, H., Sone, H., Neda, H., Yamauchi, N., Maeda, M., and Urushizaki, I. Synergistic effects of recombinant human tumor necrosis factor and hyperthermia on in vitro cytotoxicity and artificial metastasis. Cancer Res., 48: 654–657, 1988.
135. Tomasovic, S. P., Barta, M., and Klostergaard, J. Neutral red uptake and clonogenic survival assays of the hyperthermia sensitization of tumor cells to tumor necrosis factor. Radiat. Res., 119: 325–337, 1989.
136. Fujimoto, S., Konno, O., Kobayashi, K., Kokubun, M., Shrestha, R. D., Kiuchi, S., Takahashi, M., Ohta, M., and Okui, K. Augmented antitumor effects of combined treatment with hyperthermia and tumor necrosis factor on human gastric cancer xenotransplanted into nude mice. Int. J. Hyperthermia, 7: 511–518, 1991.
137. Cohen, J. D., Robins, H. I., and Schmitt, C. L. Tumoricidal interactions of hyperthermia with carboplatin, cisplatin and etoposide. Cancer Lett., 44: 205–210, 1989.
138. Kampinga, H. H., Kruk, G. V. D., and Konings, A. W. T. Reduced DNA break formation and cytotoxicity of the topoisomerase II drug 4′-(9′-acridinylamino)methanesulfon-m-anisidide when combined with hyperthermia in human and rodent cell lines. Cancer Res., 49: 1712–1717, 1989.
139. Dynlacht, J. R., Wong, R. S. L., Albright, N., and Dewey, W. C. Hyperthermia can reduce cytotoxicity from etoposide without a corresponding reduction in the number of topoisomerase II-DNA cleavable complexes. Cancer Res., 54: 4129–4137, 1994.
140. Teicher, B. A., Holden, S. A., Khandakar, V., and Herman, T. S. Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diaminedichloro-platinum(II)/heat/radiation] in a murine tumor. J. Cancer Res. Clin. Oncol., 119: 645–651, 1993.